PALI Palisade Bio
- 6.2200
- -0.4900-7.30%
- 6.1200
- -0.1000-1.61%
Palisade Bio News
Palisade Bio | 10-Q: Quarterly report
Palisade Bio Welcomes New Board Member, Eyes Strategic Growth
Palisade Bio Appoints Margery Fischbein to Its Board of Directors
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globallyCarlsbad, CA, May 07, 2024 — Pal
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 02, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter.AMD guided
SYT and STI Among Mid-day Movers
Maxim Group: Reiterates Palisade Bio (PALI.US) rating, adjusted from buy to buy rating, target price of $22.50.
Maxim Group: Reiterates Palisade Bio (PALI.US) rating, adjusted from buy to buy rating, target price of $22.50.
Maxim Group Reiterates Buy on Palisade Bio, Maintains $22.5 Price Target
Maxim Group analyst Naz Rahman reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $22.5 price target.
Palisade Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 204.84% Maxim Group → $22.5 Reiterates Buy → Buy 04/16/2024 204.84% Maxim Group $22.5 → $22.5 M
Decoding The Surge: Palisade Bio (PALI) Shares On The Move
The current trading session has witnessed a notable surge in the shares of Palisade Bio, Inc. (NASDAQ: PALI), with an impressive increase of 21.46%, elevating its value to $7.32. This substantial uptick in PALI stock price follows the successful completion of an analysis for the development of a new drug. Today, Palisade Bio (PALI) has ...
US Stocks Mixed; Amazon Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 0.1% on Wednesday.Following the market opening Wednesday, the Dow traded up 0.09% to 37,851.28 while the NASDAQ rose 0.04% to 1
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts
US stocks look set to open modestly lower in Wednesday's trading session despite better-than-expected private employment figures, as investors anxiously await the Federal Reserve's rate policy decisio
Palisade Bio Stock Rallies 50% Premarket on Colitis Drug Update
Market-Moving News for May 1 St
TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product revenue outlook.SBUX: -13% | Starbucks shares are trading lower following we
Palisade Bio Shares Are Trading Higher After the Company Announced Completion of Its Analysis to Determine the Effects of Bioactivated PALI-2108 on TNF-α Production in a Whole Blood Assay.
Palisade Bio Shares Are Trading Higher After the Company Announced Completion of Its Analysis to Determine the Effects of Bioactivated PALI-2108 on TNF-α Production in a Whole Blood Assay.
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged With Pro-Inflammatory Lipopolysaccharide (LPS)
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year endCarlsbad, CA, May 01, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("P
ING, PALI and FNCH Among Pre-market Losers
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.Nucor reported quarterly earnings of $3.46 per s
Analysis
Price Target
No Data
